Trials / Not Yet Recruiting
Not Yet RecruitingNCT07257068
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
Detailed description
Primary Objective 1\. To estimate the efficacy of infliximab in reversing insulin dependence in CIADM. Secondary Objective 1. To evaluate the safety of infliximab when used for CIADM. 2. To estimate the duration of time off insulin for patients who are able to discontinue insulin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Infliximab | Given by IV |
Timeline
- Start date
- 2026-04-14
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
- First posted
- 2025-12-02
- Last updated
- 2025-12-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07257068. Inclusion in this directory is not an endorsement.